Biogen (BIIB) PT Raised to $500 at Cowen Amid BIIB037 Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Biogen (BIIB) Price Target Lifted to $532 at Leerink Partners on Strong Showing for BIIB037
March 20, 2015 10:28 AM EDTLeerink Partners analyst Joseph Schwartz reiterated an Outperform rating and lifted his price target on Biogen (NASDAQ: BIIB) to $532.00 (from $475.00)
Schwartz said, "This morning at the ADPD15 meeting, BIIB reported better than expected results from BIIB037s Ph. Ib trial on both... More
Biogen (BIIB) PT Lifted to $512 at Citi; Questions Remain on Dose/Saftey
March 20, 2015 9:39 AM EDTCiti reiterated a Buy rating and boosted its price target on Biogen (NASDAQ: BIIB) to $512.00 (from $410.00) following solid potency data on BIIB037, although main question in dose/safety.
"The only question is safety as 32% of patients on the high does... More
Trial Design Likely Boosted Biogen (BIIB) BIIB037 Efficacy Data - Nomura
March 20, 2015 8:01 AM EDTWhile many are signing the praises of Biogen (NASDAQ: BIIB) this morning following Phase Ib data for BIIB037 in Alzheimers disease (AD), Nomura analyst M. Ian Somaiya is not so sanguine - asking "was it the drug or the trial design?"
Somaiya commented, " The Phase Ib efficacy data exceeded even the most bullish... More
Biogen (BIIB) PT Raised to $500 at Barclays on 'Impressive' AD Data
March 20, 2015 7:34 AM EDTBarclays analyst Geoffrey Meacham reiterated an Overweight rating and boosted his price target on Biogen (NASDAQ: BIIB) to $500.00 (from $435.00) following "impressive' AD data.
"The data provided quantitative evidence of a statistically significant benefit vs placebo at 54 weeks on key connotative endpoints...",... More
Biogen (BIIB) BIIB-037 Data Shows Strong Efficacy, Very Good Safety, Says RBC
March 20, 2015 7:01 AM EDTRBC Capital maintained an Outperform rating on Biogen (NASDAQ: BIIB) with a price target of $445. Comments follow the release of BIIB-037 data in Alzheimers disease. Analyst Michael J. Yee noted data showed strong efficacy and very good safety.
"We are at the AD/PD conf in Europe & there are a few... More
Biogen Idec (BIIB) Reports Statistically Significant Data from Aducanumab Phase 1b
March 20, 2015 5:53 AM EDTBiogen Idec (NASDAQ: BIIB) announced data from a pre-specified interim analysis of PRIME, the Phase 1b study of aducanumab (BIIB037), in which aducanumab demonstrated an acceptable safety profile and positive results on radiologic and clinical measurements in patients with prodromal or mild Alzheimers disease (AD). These data are being presented today at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders in Nice, France.
Treatment with aducanumab produced a dose- and time-dependent reduction of amyloid plaque in the brain. Amyloid plaque is... More
Biogen (BIIB) Price Target Raised to $500 at Credit Suisse
March 19, 2015 6:26 AM EDTCredit Suisse analyst R. Mehrotra reiterated an Outperform rating and boosted his price target on Biogen (NASDAQ: BIIB) to $500.00 (from $400.00).
Mehrotra notes BIIB037 data (for Alzheimer's disease, AD) is upcoming and due pre-market (5:35AM EST) on Friday, March 20th.
"Two >... More
